Sponsor or institution
Clinical trials and research at Zydus Therapeutics Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Zydus Therapeutics Inc. that are recruiting, at sites in 12 countries (most in United States (5), Australia (1), Belgium (1)). By phase: Phase 1 (2), Phase 3 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 12Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Saroglitazar Magnesium for PBC with incomplete UDCA response or intolerance | Phase 3 | Lakewood Rch, Florida | Recruiting | Feb 20, 2026 |
| Saroglitazar Magnesium-V as add-on therapy for primary biliary cholangitis | Phase 3 | Marietta, Georgia and 2 other locations | Recruiting | Oct 14, 2025 |
| Usnoflast Neuromuscular Investigation for ALS treatment efficacy | Phase 2 | La Jolla, California and 48 other locations | Recruiting | Jun 17, 2025 |
| Saroglitazar pharmacokinetics and safety in moderate cholestatic cirrhosis | Phase 1 | Indianapolis, Indiana | Recruiting | Feb 13, 2025 |
| Treatment for liver impairment in patients with cirrhosis from cholestatic liver disease | Phase 1 | Indianapolis, Indiana | Recruiting | Sep 16, 2021 |
All recruiting trials (5)
-
Saroglitazar Magnesium for PBC with incomplete UDCA response or intolerance
This study tests whether Saroglitazar Magnesium can help people with primary biliary cholangitis who still have high alkaline phosphatase despite UDCA or cannot take UDCA.
-
Saroglitazar Magnesium-V as add-on therapy for primary biliary cholangitis
This trial tests whether Saroglitazar Magnesium-V, compared with placebo, can improve long-term clinical outcomes in adults with primary biliary cholangitis who are on UDCA.
-
Usnoflast Neuromuscular Investigation for ALS treatment efficacy
This study tests Usnoflast at different doses against placebo to see if it helps adults with ALS.
-
Saroglitazar pharmacokinetics and safety in moderate cholestatic cirrhosis
This tests whether taking saroglitazar 1 mg every other day is safe and how the drug behaves in adults with moderate cirrhosis from cholestatic liver disease.
-
Treatment for liver impairment in patients with cirrhosis from cholestatic liver disease
This study is testing a new medication called Saroglitazar Magnesium to see if it can improve liver function and health in people with cirrhosis from cholestatic liver disease.
Quick answers
How many clinical trials run by Zydus Therapeutics Inc. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 12 countries. The most sites are in United States (5 trials), Australia (1 trial), Belgium (1 trial), Canada (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.